CTX.TO (Mkap C$ 7.7 M) 1x FDA approved /2x Phase 3 und weitere Produkte am Markt (Seite 7)
eröffnet am 10.01.18 20:30:45 von
neuester Beitrag 17.03.24 19:06:07 von
neuester Beitrag 17.03.24 19:06:07 von
Beiträge: 157
ID: 1.271.450
ID: 1.271.450
Aufrufe heute: 0
Gesamt: 23.365
Gesamt: 23.365
Aktive User: 0
ISIN: CA2258471028 · WKN: A2AD5R · Symbol: CTX
0,4300
CAD
0,00 %
0,0000 CAD
Letzter Kurs 03.05.24 Toronto
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 13,110 | +38,44 | |
| 6,5000 | +27,45 | |
| 1,2100 | +21,00 | |
| 48,25 | +19,94 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 24,050 | -12,55 | |
| 4,0300 | -12,96 | |
| 6,2600 | -14,25 | |
| 3,8500 | -14,45 | |
| 36,70 | -22,87 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 62.754.694 von Saaartlesip am 22.02.20 02:06:07In wenigen tagen kommen die Quartalszahlen sollten diese wieder positiv sein gibts bestimmt n Kurssprung
Bin heute auch eingestiegen!
Antwort auf Beitrag Nr.: 62.717.542 von Biohero am 18.02.20 20:49:22Solche kleine unterbewertete Unternehmen denke ich sind eher die bessere Wahl wenns turbulenzen an den Aktienmärkten gibt . CTX bewegt sich seit längerem in dieser $0.90-1 range wird Zeit für den Ausbruch nach oben .
Antwort auf Beitrag Nr.: 62.675.311 von Jim_Panse am 13.02.20 21:23:52Bin nach langer Zeit wieder bei dieser kleinen superattraktiver Perle wieder eingestiegen .Nächsten monat kommen die Zahlen die könnten eventuell wieder für einen ordentlichen Push sorgen so odersoist die Aktie einfach nur verdammt günstig .
Marktkap knapp C$20 M (= €13,9 M ) --Cash $13 M -- Aktienanzahl 20,8 M --Profitabel
Präsentation
http://www.crescitatherapeutics.com/wp-content/uploads/2019/…
Insiderkäufe
https://ceo.ca/api/sedi?insider=&symbol=CTX&date=&transactio…
Crescita Signs Exclusive Distribution Agreement with FILLMED
http://crescitatherapeutics.mediaroom.com/2020-01-20-Crescit…
The Company anticipates launching both products on the Canadian market following approval by Health Canada anticipated by late 2020 or early 2021.
Marktkap knapp C$20 M (= €13,9 M ) --Cash $13 M -- Aktienanzahl 20,8 M --Profitabel
Präsentation
http://www.crescitatherapeutics.com/wp-content/uploads/2019/…
Insiderkäufe
https://ceo.ca/api/sedi?insider=&symbol=CTX&date=&transactio…
Crescita Signs Exclusive Distribution Agreement with FILLMED
http://crescitatherapeutics.mediaroom.com/2020-01-20-Crescit…
The Company anticipates launching both products on the Canadian market following approval by Health Canada anticipated by late 2020 or early 2021.
Crescita Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Studies for its Lead Pipeline Product in Patients with Plaque Psoriasis
LAVAL, QC, Feb. 11, 2020 /CNW/ – Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) ("Crescita" or the "Company"), a commercial dermatology company with manufacturing capabilities and a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced positive topline results from two pivotal Phase 3 clinical trials for an ultra-potent topical corticosteroid product being developed for the treatment of plaque psoriasis using the Company's patented Multiplexed Molecular Penetration Enhancer ("MMPE™") technology. The studies were conducted by the Company's partners including Ferndale Laboratories, Inc. ("Ferndale").http://crescitatherapeutics.mediaroom.com/2020-02-11-Crescit…
Trading Spotlight
Crescita Reports 2019 Third Quarter Results
Revenue up 9.9% Year-over-Year
Positive Adjusted EBITDA1 of $0.9 Million
Q3-F2019 Year-over-Year and Operational Highlights:
Revenue was $4,906, an increase of $442 or 9.9% versus Q3-2018;
Recognized a $1,324 (US$1,000) sales milestone from Taro Pharmaceuticals Inc. (Taro), our U.S. licensee, for achieving the 4th and final cumulative target for the U.S. sales of Pliaglis® (included in revenue above);
Operating expenses were $4,428, an increase of $472 or 11.9% versus Q3-2018;
Adjusted EBITDA1 was $939, an increase of $93 versus Q3-2018;
Generated $1,316 in cash during the quarter, resulting in an ending cash and cash equivalents balance of $13,005 as at September 30, 2019, compared to $11,689 at the end of Q2-2019;
On July 4, 2019, the Company received the second tranche of the up-front payment from Cantabria Labs of $1,695, triggered by the first commercial sale of Pliaglis in Italy;
On July 16, 2019, the Company announced that the United States Patent and Trademark Office granted U.S. Patent No. 10,350,180 for an enhanced formulation of Pliaglis, providing extended patent protection to 2031.
Key Events Subsequent to Q3-F2019
On October 28, 2019, the Company announced a development and licensing agreement granting Sundial worldwide rights to the Company's proprietary transdermal delivery technologies, MMPE™ and DuraPeel™, for the development of topical products containing cannabis and/or hemp;
On November 5, 2019, the Company announced that the U.S. Food and Drug Administration approved the enhanced formulation of Pliaglis®, triggering a milestone of $US750 under the out-licensing agreement with Taro.
"We are making progress toward our goal of becoming a leading Canadian commercial dermatology company," said Serge Verreault, President and Chief Executive Officer of Crescita. "We delivered top line organic growth and positive cash flow in the quarter and continue to focus on expanding our product and royalty revenue streams. Our strategy includes the geographic expansion of Pliaglis in the rest-of-world and further leveraging our patented active delivery technologies for other markets and indications."
https://www.newswire.ca/news-releases/crescita-reports-2019-…
Revenue up 9.9% Year-over-Year
Positive Adjusted EBITDA1 of $0.9 Million
Q3-F2019 Year-over-Year and Operational Highlights:
Revenue was $4,906, an increase of $442 or 9.9% versus Q3-2018;
Recognized a $1,324 (US$1,000) sales milestone from Taro Pharmaceuticals Inc. (Taro), our U.S. licensee, for achieving the 4th and final cumulative target for the U.S. sales of Pliaglis® (included in revenue above);
Operating expenses were $4,428, an increase of $472 or 11.9% versus Q3-2018;
Adjusted EBITDA1 was $939, an increase of $93 versus Q3-2018;
Generated $1,316 in cash during the quarter, resulting in an ending cash and cash equivalents balance of $13,005 as at September 30, 2019, compared to $11,689 at the end of Q2-2019;
On July 4, 2019, the Company received the second tranche of the up-front payment from Cantabria Labs of $1,695, triggered by the first commercial sale of Pliaglis in Italy;
On July 16, 2019, the Company announced that the United States Patent and Trademark Office granted U.S. Patent No. 10,350,180 for an enhanced formulation of Pliaglis, providing extended patent protection to 2031.
Key Events Subsequent to Q3-F2019
On October 28, 2019, the Company announced a development and licensing agreement granting Sundial worldwide rights to the Company's proprietary transdermal delivery technologies, MMPE™ and DuraPeel™, for the development of topical products containing cannabis and/or hemp;
On November 5, 2019, the Company announced that the U.S. Food and Drug Administration approved the enhanced formulation of Pliaglis®, triggering a milestone of $US750 under the out-licensing agreement with Taro.
"We are making progress toward our goal of becoming a leading Canadian commercial dermatology company," said Serge Verreault, President and Chief Executive Officer of Crescita. "We delivered top line organic growth and positive cash flow in the quarter and continue to focus on expanding our product and royalty revenue streams. Our strategy includes the geographic expansion of Pliaglis in the rest-of-world and further leveraging our patented active delivery technologies for other markets and indications."
https://www.newswire.ca/news-releases/crescita-reports-2019-…
U.S. Food and Drug Administration Approves Enhanced Formulation of Pliaglis®
...The approval of the Enhanced Formulation triggers a US$0.75 million milestone under the terms of the out-licensing agreement in place with Taro...
https://www.newswire.ca/news-releases/u-s-food-and-drug-admi…
...The approval of the Enhanced Formulation triggers a US$0.75 million milestone under the terms of the out-licensing agreement in place with Taro...
https://www.newswire.ca/news-releases/u-s-food-and-drug-admi…
Antwort auf Beitrag Nr.: 61.815.010 von Niller84 am 01.11.19 13:08:25Zweites Halbjahr natürlich 😉
Antwort auf Beitrag Nr.: 61.805.407 von techxxnine am 31.10.19 09:31:31Ich bin guter Dinge, denn das Unternehmen hat über 10 Mio. an Cash zur Verfügung und ist in der Gewinnzone (1 H 2,2 Mio Gewinn) und forscht munter weiter und lizensiert seine Produkte aus. Wenn der Gewinn ähnlich stark ist im 2 Quartal, dann haben wir hier ein stark wachsendes Unternehmen mit einem KGV von unter 5! Leider ist Crescita sehr unbekannt, aber das ist eben auch unsere Chance...
Ich überlege mir hier einen Einsteig. Guter Zeitpunkt?
Durchsuchen
